Skip to content

Study · Randomized controlled trial · n = 4,372 · 2016

5 results

Exposure-response analyses of liraglutide 3.0 mg for weight management.

Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW

Diabetes, obesity & metabolism1 Mar 2016Cited by 74 (Europe PMC)

PMID26833744 (opens in a new tab)PMCIDPMC5069568 (opens in a new tab)DOI10.1111/dom.12639 (opens in a new tab)PepBankPUB-26833744
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, weight loss increased with greater liraglutide exposure and appeared to level off at the highest exposures in most individuals, but did not fully plateau in men.

    In plain wordsIn adults with overweight or obesity, more liraglutide in the blood went with more weight loss, levelling off at the highest levels in most people.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss by liraglutide exposure
    Study

    n = 4,372

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2, 1.8, 2.4 and 3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Weight loss increased with greater exposure and appeared to level off at the highest exposures associated with liraglutide 3.0 mg in most individuals, but did not fully plateau in men.
    1 context sentence
    Summary · context
    We report efficacy and safety responses across a wide range of exposure levels, using data from one phase II (liraglutide doses 1.2, 1.8, 2.4 and 3.0 mg), and two phase IIIa [SCALE Obesity and Prediabetes (3.0 mg); SCALE Diabetes (1.8; 3.0 mg)] randomized, placebo-controlled trials (n = 4372).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, HbA1c reduction increased with higher plasma liraglutide concentration, plateauing at about 21 nM, but did not fully plateau when baseline HbA1c was above 8.5%.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, higher liraglutide blood levels went with a bigger HbA1c drop, levelling off at 21 nM.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction by plasma liraglutide concentration
    Study

    n = 4,372

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2, 1.8, 2.4 and 3.0 mgAs given in this study (human).

    Measurements

    Plateau plasma liraglutide concentration
    21 nM
    HbA1c reduction

    Source sentences

    Summary
    HbA1c reduction increased with higher plasma liraglutide concentration (plateauing at ∼21 nM); however, for individuals with baseline HbA1c >8.5%, HbA1c reduction did not fully plateau.
    1 context sentence
    Summary · context
    We report efficacy and safety responses across a wide range of exposure levels, using data from one phase II (liraglutide doses 1.2, 1.8, 2.4 and 3.0 mg), and two phase IIIa [SCALE Obesity and Prediabetes (3.0 mg); SCALE Diabetes (1.8; 3.0 mg)] randomized, placebo-controlled trials (n = 4372).
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with overweight or obesity, no exposure-response relationship was identified for any liraglutide safety outcome except gastrointestinal adverse events.

    In plain wordsIn adults with overweight or obesity, higher liraglutide levels were not linked to more side effects, except stomach and gut effects.

    Peptide
    Liraglutide
    Outcome
    No significant changeExposure-response of safety outcomes other than GI adverse events
    Study

    n = 4,372

    Outcome group
    Adverse events · Whole body
    Studied dose
    1.2, 1.8, 2.4 and 3.0 mgAs given in this study (human).

    Source sentences

    Summary
    No exposure-response relationship was identified for any safety outcome, with the exception of gastrointestinal adverse events (AEs).
    1 context sentence
    Summary · context
    We report efficacy and safety responses across a wide range of exposure levels, using data from one phase II (liraglutide doses 1.2, 1.8, 2.4 and 3.0 mg), and two phase IIIa [SCALE Obesity and Prediabetes (3.0 mg); SCALE Diabetes (1.8; 3.0 mg)] randomized, placebo-controlled trials (n = 4372).
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with overweight or obesity, gastrointestinal adverse events were the one safety outcome with an exposure-response relationship for liraglutide.

    In plain wordsIn adults with overweight or obesity, stomach and gut side effects were the one safety outcome linked to liraglutide blood levels.

    Peptide
    Liraglutide
    Outcome
    Not applicableExposure-response of gastrointestinal adverse events
    Study

    n = 4,372

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.2, 1.8, 2.4 and 3.0 mgAs given in this study (human).

    Source sentences

    Summary
    No exposure-response relationship was identified for any safety outcome, with the exception of gastrointestinal adverse events (AEs).
    1 context sentence
    Summary · context
    We report efficacy and safety responses across a wide range of exposure levels, using data from one phase II (liraglutide doses 1.2, 1.8, 2.4 and 3.0 mg), and two phase IIIa [SCALE Obesity and Prediabetes (3.0 mg); SCALE Diabetes (1.8; 3.0 mg)] randomized, placebo-controlled trials (n = 4372).
  5. 05HumanRandomized controlled trialSafety outcome

    In adults with overweight or obesity, those with gallbladder adverse events, acute pancreatitis or neoplasms did not have higher liraglutide exposure than the overall population.

    In plain wordsIn adults with overweight or obesity, people with gallbladder problems, pancreatitis or tumours did not have higher liraglutide levels than the overall group.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiraglutide exposure in individuals with gallbladder AEs, pancreatitis or neoplasms
    Study

    n = 4,372

    Outcome group
    Adverse events · Whole body
    Studied dose
    1.2, 1.8, 2.4 and 3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Individuals with gallbladder AEs, acute pancreatitis or malignant/breast/benign colorectal neoplasms did not have higher liraglutide exposure compared with the overall population.
    1 context sentence
    Summary · context
    We report efficacy and safety responses across a wide range of exposure levels, using data from one phase II (liraglutide doses 1.2, 1.8, 2.4 and 3.0 mg), and two phase IIIa [SCALE Obesity and Prediabetes (3.0 mg); SCALE Diabetes (1.8; 3.0 mg)] randomized, placebo-controlled trials (n = 4372).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 19 Jan 2018
CompletedPhase 3Results postedNCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Novo Nordisk A/Sn = 8461 Jun 2011 to 25 Jan 2013

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 29 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.